William G. Bornmann

18.3k total citations · 6 hit papers
167 papers, 14.7k citations indexed

About

William G. Bornmann is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, William G. Bornmann has authored 167 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Molecular Biology, 49 papers in Oncology and 41 papers in Organic Chemistry. Recurrent topics in William G. Bornmann's work include Chronic Myeloid Leukemia Treatments (32 papers), Cancer therapeutics and mechanisms (22 papers) and Chronic Lymphocytic Leukemia Research (19 papers). William G. Bornmann is often cited by papers focused on Chronic Myeloid Leukemia Treatments (32 papers), Cancer therapeutics and mechanisms (22 papers) and Chronic Lymphocytic Leukemia Research (19 papers). William G. Bornmann collaborates with scholars based in United States, Russia and France. William G. Bornmann's co-authors include John Kuriyan, Bayard Clarkson, Thomas H. Schindler, Darren R. Veach, W. Todd Miller, Patricia Pellicena, Bhushan Nagar, Martin E. Kuehne, David A. Boothman and Samuel J. Danishefsky and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

William G. Bornmann

167 papers receiving 14.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

2000 1.4k citations William G. Bornmann et al. profile →
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

2002 731 citations William G. Bornmann et al. PubMed profile →
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase

2003 654 citations William G. Bornmann et al. profile →
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction

2009 552 citations Ismael Samudio, Marina Konopleva et al. Journal of Clinical Investigation profile →
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

2007 535 citations William G. Bornmann, Jacqueline Bromberg et al. Journal of Clinical Investigation profile →
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

1997 530 citations William G. Bornmann et al. profile →

Peers

Countries citing papers authored by William G. Bornmann

Since Specialization

Citations

This map shows the geographic impact of William G. Bornmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William G. Bornmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William G. Bornmann more than expected).

Fields of papers citing papers by William G. Bornmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William G. Bornmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William G. Bornmann. The network helps show where William G. Bornmann may publish in the future.

Co-authorship network of co-authors of William G. Bornmann

This figure shows the co-authorship network connecting the top 25 collaborators of William G. Bornmann. A scholar is included among the top collaborators of William G. Bornmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William G. Bornmann. William G. Bornmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer 2016 ·Molecular Cancer Therapeutics ·Long-Shan Li, (unknown), (unknown), Shuangping Liu, Hyunsil Park, Stephen G. Chun, William G. Bornmann, Joel Thibodeaux, Jingsheng Yan, Gaurab Chakrabarti, Xian-Jin Xie, Baran D. Sumer, David A. Boothman, John S. Yordy	45
2	Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells 2014 ·Molecular Cancer Therapeutics ·Weiguo Zhang, Vivian Ruvolo, Gao Chen, Liran Zhou, William G. Bornmann, Twee Tsao, Wendy Schober, Paul D. Smith, Sylvie M. Guichard, Marina Konopleva, Michael Andreeff	30
3	Tumor-Selective, Futile Redox Cycle-Induced Bystander Effects Elicited by NQO1 Bioactivatable Radiosensitizing Drugs in Triple-Negative Breast Cancers 2014 ·Antioxidants and Redox Signaling ·Lifen Cao, Long Shan Li, (unknown), Ling Xiao, Gaurab Chakrabarti, Erik A. Bey, Kathryn E. Reinicke, Melissa C. Srougi, Zachary Moore, Ying Dong, (unknown), Wareef Kabbani, Chin-Rang Yang, Xiaoyu Wang, Farjana Fattah, Julio C. Morales, Edward A. Motea, William G. Bornmann, John S. Yordy, David A. Boothman	32
4	Designing and Developing S100P Inhibitor 5-Methyl Cromolyn for Pancreatic Cancer Therapy 2013 ·Molecular Cancer Therapeutics ·Thiruvengadam Arumugam, Vijaya Ramachandran, Duoli Sun, Zhenghong Peng, Ashutosh Pal, David S. Maxwell, William G. Bornmann, Craig D. Logsdon	41
5	Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers 2013 ·Molecular Cancer Therapeutics ·Erik A. Bey, Kathryn E. Reinicke, Melissa C. Srougi, Marie E. Varnes, Vernon Anderson, John J. Pink, Long Shan Li, Malina Patel, Lifen Cao, Zachary Moore, Amy Rommel, (unknown), Cheryl Lewis, David Euhus, William G. Bornmann, Donald J. Buchsbaum, Douglas R. Spitz, Jinming Gao, David A. Boothman	84
6	Asymmetric synthesis of the C1–C6 portion of the psymberin using an Evans chiral auxiliary 2013 ·Tetrahedron Letters ·Ashutosh Pal, Zhenghong Peng, (unknown), (unknown), William G. Bornmann	6
7	Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy 2011 ·Clinical Cancer Research ·Long Shan Li, Erik A. Bey, Ying Dong, Jieru Meng, Biswanath Patra, Jingsheng Yan, Xian‐Jin Xie, Rolf A. Brekken, Carlton C. Barnett, William G. Bornmann, Jinming Gao, David A. Boothman	94
8	STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17 2011 ·Cancer Research ·Bingbing Dai, Jieru Meng, Michael Peyton, Luc Girard, William G. Bornmann, Lin Ji, John D. Minna, Bingliang Fang, Jack A. Roth	80
9	Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against Tuberculosis 2011 ·Cell Host & Microbe ·Ruth J. Napier, Wasiulla Rafi, (unknown), Kimberly R. Powell, (unknown), William G. Bornmann, Padmini Salgame, Thomas M. Shinnick, Daniel Kalman	5
10	Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis 2010 ·Cancer Research ·Vaibhav Kapuria, Luke F. Peterson, Dexing Fang, William G. Bornmann, Moshe Talpaz, Nicholas J. Donato	317
11	Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo : Therapeutic Implications 2010 ·Molecular Cancer Therapeutics ·Lan V. Pham, Archito T. Tamayo, Changping Li, William G. Bornmann, Waldemar Priebe, R. Ford	46
12	β-Lapachone Micellar Nanotherapeutics for Non–Small Cell Lung Cancer Therapy 2010 ·Cancer Research ·Elvin Blanco, Erik A. Bey, Chalermchai Khemtong, (unknown), (unknown), Huabing Chen, Chase W. Kessinger, Kevin Carnevale, William G. Bornmann, David A. Boothman, Jinming Gao	115
13	Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax) 2008 ·Cancer Research ·Marina Konopleva, Julie C. Watt, Rooha Contractor, Twee Tsao, David Harris, Zeev Estrov, William G. Bornmann, Hagop Kantarjian, Jean Viallet, Ismael Samudio, Michael Andreeff	215
14	Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells 2008 ·Molecular Cancer Therapeutics ·Dongwei Zhang, Ashutosh Pal, William G. Bornmann, Fumiyuki Yamasaki, Francisco J. Esteva, Gabriel N. Hortobágyi, Chandra Bartholomeusz, Naoto T. Ueno	69
15	Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target 2007 ·Cancer Research ·Ariel Fernández, Ángela Sanguino, Zhenghong Peng, Alejandro Crespo, Eylem Öztürk, Xi Zhang, Shimei Wang, William G. Bornmann, Gabriel Lopez‐Berestein	32
16	An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic 2007 ·Journal of Clinical Investigation ·Ariel Fernández, Ángela Sanguino, Zhenghong Peng, Eylem Öztürk, Jianping Chen, Alejandro Crespo, Sarah Wulf, Aleksander Shavrin, (unknown), Jianpeng Ma, Jonathan C. Trent, Yvonne G. Lin, Hee Dong Han, Lingegowda S. Mangala, James A. Bankson, Juri G. Gelovani, Allen M. Samarel, William G. Bornmann, Anil K. Sood, Gabriel Lopez‐Berestein	107
17	Enteropathogenic Escherichia coli Tir is an SH2/3 ligand that recruits and activates tyrosine kinases required for pedestal formation 2007 ·Molecular Microbiology ·Bettina Bommarius, David S. Maxwell, Alyson Swimm, Sara W. Leung, Anita H. Corbett, William G. Bornmann, Daniel Kalman	49
18	Pyridone 6, A Pan-Janus–Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells 2006 ·Cancer Research ·Laura Pedranzini, Tobias Dechow, Marjan Berishaj, Raymond L. Comenzo, Ping Zhou, Janeen Azare, William G. Bornmann, Jacqueline Bromberg	133
19	Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics 2004 ·Journal of Clinical Investigation ·(unknown), Yuhong She, Michael J. Soskis, Christopher P. Borella, Jeffrey R. Gardner, (unknown), Benzon M. Dy, Mark Heaney, Mark R. Philips, William G. Bornmann, Francis M. Sirotnak, David A. Scheinberg	83
20	Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. 2003 ·PubMed ·Kyoung Jin P. Yoon, (unknown), Christopher L. Morton, William G. Bornmann, Richard Lee, Philip M. Potter, Mary K. Danks	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact